These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 32298693

  • 1. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
    Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C, Sun Z, Pang X.
    Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
    [Abstract] [Full Text] [Related]

  • 2. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
    Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X.
    J Clin Invest; 2020 Apr 01; 130(4):1752-1766. PubMed ID: 31874110
    [Abstract] [Full Text] [Related]

  • 3. Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
    Alhayyani S, McLeod L, West AC, Balic JJ, Hodges C, Yu L, Smith JA, Prodanovic Z, Bozinovski S, Kumar B, Ruwanpura SM, Saad MI, Jenkins BJ.
    Oncogene; 2022 Feb 01; 41(6):809-823. PubMed ID: 34857889
    [Abstract] [Full Text] [Related]

  • 4. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z, Yin M, Chu P, Lou M.
    Aging (Albany NY); 2019 Sep 04; 11(17):7187-7196. PubMed ID: 31484165
    [Abstract] [Full Text] [Related]

  • 5. Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis.
    Kim H, Jang B, Zhang C, Caldwell B, Park DJ, Kong SH, Lee HJ, Yang HK, Goldenring JR, Choi E.
    Gastroenterology; 2024 Jan 04; 166(1):117-131. PubMed ID: 37802423
    [Abstract] [Full Text] [Related]

  • 6. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
    Iskandar K, Rezlan M, Yadav SK, Foo CH, Sethi G, Qiang Y, Bellot GL, Pervaiz S.
    Antioxid Redox Signal; 2016 May 10; 24(14):781-94. PubMed ID: 26714745
    [Abstract] [Full Text] [Related]

  • 7. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
    Xu Y, Zong S, Gao X, Zhang H, Wang B, Li P, Liu T, Li S.
    Gene; 2019 Mar 10; 688():1-6. PubMed ID: 30415007
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
    Mi C, Cao X, Ma K, Wei M, Xu W, Lin Y, Zhang J, Wang TY.
    Chem Biol Interact; 2022 Jan 05; 351():109729. PubMed ID: 34717917
    [Abstract] [Full Text] [Related]

  • 10. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
    Liu S, Gandler HI, Tošić I, Ye DQ, Giaccone ZT, Frank DA.
    Mol Cancer Res; 2021 Aug 05; 19(8):1283-1295. PubMed ID: 33931487
    [Abstract] [Full Text] [Related]

  • 11. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL, Luo LX, Li Y, Liu ZQ, Li LL, Shi DF, Xie Y, Huang M, Lu LL, Duan FG, Huang JM, Fan XX, Yuan ZW, Ding J, Yao XJ, Ward DC, Liu L.
    Int J Cancer; 2019 Sep 01; 145(5):1334-1345. PubMed ID: 30786019
    [Abstract] [Full Text] [Related]

  • 12. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Tian D, Tang J, Geng X, Li Q, Wang F, Zhao H, Narla G, Yao X, Zhang Y.
    Cancer Lett; 2020 Nov 28; 493():80-90. PubMed ID: 32814087
    [Abstract] [Full Text] [Related]

  • 13. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer.
    Cenigaonandia-Campillo A, Serna-Blasco R, Gómez-Ocabo L, Solanes-Casado S, Baños-Herraiz N, Puerto-Nevado LD, Cañas JA, Aceñero MJ, García-Foncillas J, Aguilera Ó.
    Theranostics; 2021 Nov 28; 11(8):3595-3606. PubMed ID: 33664850
    [Abstract] [Full Text] [Related]

  • 14. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.
    PLoS One; 2013 Nov 28; 8(11):e80885. PubMed ID: 24260500
    [Abstract] [Full Text] [Related]

  • 15. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3.
    Harada Y, Ishii I, Hatake K, Kasahara T.
    Cancer Lett; 2012 Jun 01; 319(1):83-8. PubMed ID: 22210382
    [Abstract] [Full Text] [Related]

  • 16. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X.
    Mol Cancer; 2019 Apr 10; 18(1):85. PubMed ID: 30971271
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 18. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.
    Yu DH, Macdonald J, Liu G, Lee AS, Ly M, Davis T, Ke N, Zhou D, Wong-Staal F, Li QX.
    PLoS One; 2008 Aug 28; 3(12):e3951. PubMed ID: 19079611
    [Abstract] [Full Text] [Related]

  • 19. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X, Liu M.
    Chin J Cancer; 2016 Oct 28; 35(1):92. PubMed ID: 27793187
    [Abstract] [Full Text] [Related]

  • 20. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M.
    Nat Commun; 2016 May 19; 7():11363. PubMed ID: 27193833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.